Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2018

 As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility during the period October 01, 2017 to March 31, 2018 (both days inclusive) are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share...
06-04-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant S Sanghvi
02-04-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia
23-03-2018

Sun Pharma: One down, Halol to go

 Sun Pharma has passed a key milestone with the Ilumya drug approval, but its investors seem to be fixated on its ability to get the USFDA approval for the Halol plant
23-03-2018

Sun Pharma likely to see a boost in morning trade after innovative drug approval

 Suh Pharma just hit a new milestone with the US FDA - it announced its first U.S. approval for an innovative medicine, Iiumya, to treat moderate to severe cases of the skin condition plaque psoriasis, in patients who are also candidates for systemic therapy or phototherapy. Phase 3 clinical studies of the drug with patients showed significant improvement, the company said. Sun Pharma has seen a negative trendline in share price over the past year, losing 28% compared to 12 months ago. The company has been struggling in its generic business due to FDA observations on its Indian plants, specially with regard to the Halol unit. SunPharma may see some relief here in the coming months, with likely resolution for Halol.
22-03-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 We are pleased to enclose herewith our Press Release relating to USFDA Approval for ILUMYA (tildrakizumab-asmn), which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,
21-03-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia
15-03-2018
Bigul

Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copies of the notice published in Financial Express-English Daily(All Editions including Gujarati Edition) in English language on March 9, 2018 and in Financial Express (Gujarati Edition) in Gujarati language on March 10, 2018 in accordance with the Investor Education and Protection Fund (IEPF) Authority (Accounting,...
10-03-2018
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant Sanghvi
08-03-2018
Bigul

Broker's Call: Sun Pharma (Buy)

 Motilal OswalSun Pharma (Buy)CMP: 525.10Target: 675The US Food and Drug Administration (USFDA) inspecte
07-03-2018
Next Page
Close

Let's Open Free Demat Account